- Report
- September 2025
- 94 Pages
Global
From €16028EUR$17,995USD£13,869GBP
- Report
- June 2025
- 88 Pages
Global
From €3113EUR$3,495USD£2,694GBP
- Report
- June 2025
- 237 Pages
Global
From €3218EUR$3,613USD£2,784GBP
€3785EUR$4,250USD£3,276GBP
- Report
- October 2025
- 100 Pages
United States
From €5299EUR$5,950USD£4,586GBP
- Report
- July 2025
- 200 Pages
United States
From €2218EUR$2,490USD£1,919GBP
- Report
- August 2025
- 200 Pages
United States
From €2218EUR$2,490USD£1,919GBP
- Report
- July 2025
- 82 Pages
United States
From €3117EUR$3,500USD£2,697GBP
- Report
- June 2025
- 250 Pages
United States
From €2484EUR$2,789USD£2,150GBP
- Report
- April 2026
- 266 Pages
United States
From €4320EUR$4,850USD£3,738GBP
- Report
- March 2026
- 150 Pages
United States
From €4320EUR$4,850USD£3,738GBP
- Report
- February 2026
- 240 Pages
United States
From €4320EUR$4,850USD£3,738GBP
- Report
- January 2024
- 348 Pages
Global
From €5203EUR$6,046USD£4,350GBP
- Report
- January 2023
- 248 Pages
Global
From €4725EUR$5,490USD£3,950GBP
From €450EUR$541USD£403GBP
- Report
- October 2021
- 72 Pages
Global
From €713EUR$800USD£617GBP
- Report
- August 2023
- 115 Pages
Global
From €2004EUR$2,250USD£1,734GBP
- Report
- November 2022
- 98 Pages
Global
From €4899EUR$5,500USD£4,239GBP
- Report
- November 2022
- 148 Pages
Global
From €4899EUR$5,500USD£4,239GBP
- Report
- October 2024
- 90 Pages
Global
From €5299EUR$5,950USD£4,586GBP
- Report
- October 2024
- 100 Pages
Global
From €5299EUR$5,950USD£4,586GBP

The Respiratory Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs used to treat respiratory diseases. These drugs are used to treat a variety of conditions, including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. Commonly prescribed respiratory drugs include bronchodilators, corticosteroids, and antibiotics.
The Respiratory Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Companies in the market include GlaxoSmithKline, AstraZeneca, Merck & Co., Novartis, and Boehringer Ingelheim. These companies are constantly researching and developing new drugs to treat respiratory diseases, as well as improving existing treatments. Show Less Read more